Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia

Human Reproduction

Volumn 14, Issue 12, 1999, Pages 2951-2958

  Ciotta, Lilliana ^b   De Leo, Vincenzo ^a   Galvani, Fabiola ^c   La Marca, Antonio ^a   Cianci, Antonio ^c  

^a UNIVERSITY OF SIENA   (Italy)

^b UNIVERSITY OF CATANIA   (Italy)

^c NONE

Author keywords

Hyperinsulinaemia; Insulin; PCOS; Sandostatin

Indexed keywords

ANDROGEN; ANDROSTENEDIONE; GLUCOSE; GONADOTROPIN; INSULIN; LUTEINIZING HORMONE; OCTREOTIDE; SEX HORMONE BINDING GLOBULIN; SOMATOSTATIN DERIVATIVE; TESTOSTERONE;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENDOCRINE SYSTEM; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; HYPERANDROGENISM; HYPERINSULINEMIA; HYPOPHYSIS; INSULIN RELEASE; LEAN BODY WEIGHT; LONG TERM CARE; METABOLISM; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE;

EID: 0032757716     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/14.12.2951     Document Type: Article

References (50)

1. Adashi, E.Y., Hsueh, A.J.W. and Yen, S.S.C. (1981) Insulin enhancement of luteinizing hormone and follicle stimulating hormone release by cultured pituitary cells. Endocrinology, 108, 1441-1449.
2. Barbieri, R.L., Makris, A., Randall, R.W. et al. (1986) Insulin stimulates androgen accumulation in incubations of ovarian stroma obtained from women with hyperandrogenism. J. Clin. Endocrinol. Metab., 62, 904-910.
3. Barnes, R.B. and Rosenfield, R.L. (1989) Pituitary-ovarian responses to nafarelin testing in the polycystic ovary syndrome. N. Engl. J. Med., 320, 559-565.
4. Bates, G. and Whitworth, M.S. (1982) Effect of body weight reduction on plasma androgens in obese, infertile women. Fertil. Steril., 38, 406-409.
5. Bathelmai, W. and Czok, R. (1962) Enzymatic determinations of glucose in the blood, cerebrospinal fluid and urine. Klin. Wochensehr, 40, 585.
6. Burghen, G.A., Givens, J.R. and Kitabchi, A.E. (1980) Correlation of hyperandrogenism with hyperinsulinism in polycystic ovarian disease. J. Clin. Endocrinol. Metab., 50, 113-116.
7. Chang, R.J., Nakamura, R.M., Judd, H.L. et al. (1989) Insulin resistance in nonobese patients with polycystic ovarian disease. J. Clin. Endocrinol. Metab., 57, 356-359.
8. Ciaraldi, T.P., El-Roeiy, A., Madar, Z. et al. (1992) Cellular mechanism of insulin resistance in polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 75, 577-583.
9. Dale. P.O., Tambo, T., Vaaler, S. et al. (1992a) Body weight, hyperinsulinemia, and gonadotropin level in the polycystic ovary syndrome: evidence of two distinct populations. Fertil. Steril., 58, 487-491.
10. Dale, P.O., Tanbo, T., Djoseland, O. et al. (1992b) Persistence of hyperinsulinemia in polycystic ovary syndrome after ovarian suppression by gonadotropin-releasing hormone agonist. Acta Endocrinol. (Copenh.), 126, 132-136.
11. De Fronzo, R.A., Barzilai, N. and Simonsom, D.C. (1991) Mechanism of metformin action in obese and lean noninsulin dependent diabetic subjects. J. Clin. Endocrinol. Metab., 73, 1294-1301.
12. Dunaif, A., Graf, M., Mandelli, J. et al. (1987) Characterization of groups of hyperandrogenic women with Acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J. Clin. Endocrinol Metab., 65, 499-507.
13. Dunaif, A., Segal, K.R., Futterweit, W. et al. (1989) Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes, 38, 1165-1174.
14. Dunaif, A., Green, G., Futterweit, W. et al. (1990) Suppression of hyperandrogenism does not improve peripheral or hepatic insulin resistance in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 70, 699-704.
15. Dunaif, A., Segal, K.R., Shelley, D.R. et al. (1992) Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes, 41, 1267-1266.
16. Dunaif, A., Xia, J., Book, C.-B. et al. (1995) Excessive insulin receptor serine phosphorylation in cultured fibroblast and in skeletal muscle: a potential mechanism for insulin resistance in the polycystic ovary syndrome. J. Clin. Invest., 96, 801-810.
17. Dunaif, A., Scott, D., Finegood, D. et al. (1996) The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 81, 3299-3306.
18. Ehrmann, D.A., Rosenfield, R.L., Barnes, R.B. et al. (1992) Detection of functional ovarian hyperandrogenism in women with androgen excess. N. Engl. J. Med., 327, 157-162.
19. Ehrmann, D.A., Schneider, D.J., Burton, E. et al. (1997)Troglilazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 82, 2108-2116.
20. Ferriman, D. and Gallwey, J.D. (1961) Clinical assessment of body hair growth in women. J. Clin. Endocrinol. Metab., 21. 1440-1447.
21. Franks, S. (1995) Polycystic ovary syndrome. N. Engl. J. Med., 333, 853-861.
22. Fulghesu, A.N., Lanzone, A., Andreani, C.L. et al. (1995) Effectiveness of a somatostatin analogue in lowering luteinizing hormone and insulin-stimulated secretion in hyperinsulinemic women with polycystic ovary disease. Fertil. Steril., 64, 703-708.
23. Geisthovel, F., Frorath, B. and Brabant, G. (1996) Acarbose reduces elevated testosterone serum concentrations in hyperinsulinaemic premenopausal women: a pilot study. Hum. Reprod., 11, 2377-2381.
24. Hoffmann, C.A. and Colca, J.R. (1992) New oral thiazolidinedione antidiabetic agents act as insulin sensitizers. Diabetes Care, 15, 1075-1078.
25. Iwamoto, Y., Kuzuya, T., Matsuda, A. et al. (1991) Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care, 14, 1083-1086.
26. Jakubowicz, D.J. and Nestler, J.E. (1997) 17α-hydroxyprogesterone response to leuprolide and serum androgens in obese women with and without polycystic ovary syndrome after dietary weight loss. J. Clin. Endocrinol. Metab., 82, 556-560.
27. Kahn, C.R., Flier, J.S., Bar, R.S. et al (1976) The syndromes of insulin resistance and acanthosis nigricans. Insulin-receptor disorders in men. N. Engl. J. Med., 294, 739-745.
28. Kiddy, D.S., Hamilton-Fairley, D., Bush, A. et al. (1992) Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome. Clin. Endocrinol. (Oxf.), 36, 105-111.
29. Marbach, P., Briner, U., Lemaire, M. et al. (1992) From somatostatin to sandostatin pharmacodynamics and pharmacokinetics. Metabolism, 41 (Suppl.), 7-9.
30. Marsden, P.J., Murdoch, A. and Taylor. (1994) Severe impairment of insulin action in adipocytes from amenorrheic subjects with polycystic ovary syndrome. Metabolism, 43, 1536-1542.
31. Morales, A.J., Laughlin, G.A., Butzow, T. et al. (1996) Insulin somatotropic, and luteinizing hormone axes in lean and obese women with polycystic ovary syndrome: common and distinct features. J. Clin. Endocrinol. Metab., 81, 2854-2864.
32. Morin-Papunen, L.C., Koivunen, R.M., Ruokonen, A. et al. (1998) Metformin therapy improves the menstrual pattern with minimal endocrine and metabolic effects in women with polycystic ovary syndrome. Fertil. Steril., 69, 691-696.
33. Morris, R.S., Carmina, E., Vijod, M.A. et al. (1995) Alterations in the sensitivity of serum insulin-like growth factor 1 and insulin like growth factor binding protein-3 to octreotide in polycystic ovary syndrome. Fertil. Steril., 63, 742-746.
34. Nagi, D.K. and Yudkin, J.S. (1993) Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects: a study of two ethnic groups. Diabetes Care, 16, 621-629.
35. National Diabetes Data Group (1979) Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes, 28, 1039-1057.
36. Nestler, J.E. (1994) Role of obesity and insulin in the development of anovulation. In Filicori, M. and Flamigni, C. (eds), Ovulation Induction: Basic Science and Clinical Advances. Elsevier, Amsterdam, The Netherlands, pp. 103-114.
37. Nestler, J.E. and Jakubowicz, D.J. (1997) Lean women with polycystic ovary syndrome respond to insulin reduction with decrease in ovarian P450c17 alpha activity and serum androgens. J. Clin. Endocrinol. Metab., 82, 4075-4079.
38. Nestler, J.E., Barlascini, CO., Matt, D.W. et al. (1989) Suppression of serum insulin by Diazoxide reduces serum testosterone levels in obese women with polycystic ovary syndrome. J. Clin. Endocrinol. Metab., 68, 1027-1032.
39. Nolan, J.J., Ludvik, B., Beerdsen, P. et al. (1994) Improvement in glucose tolerance and insulin resistance in obese subject treated with troglitazone. N. Engl. J. Med., 31, 1188-1193.
40. O'Meara, N.M., Blackman, J.D., Ehrmann, D.A. et al. (1993) Defects in b-cell function in functional ovarian hyperandrogenism. J. Clin. Endocrinol. Metab., 76, 1241-1247.
41. Ovesen, P. and Moller, N. (1997) Hyperinsulinemia in lean PCO patients? In Filicori, M. and Flamigni, C. (eds), The Ovary: Regulation. Dysfunction and Treatment. The Proceedings of the 2nd World Conference on Ovulation Induction, Bologna, Italy 12-13 September, pp. 221-228.
42. Plymate, S.R., Matej, L.A., Jones, R.E. et al. (1988) Inhibition of sex hormone-binding globulin production in the human hepatoma (Hep G2) cell line by insulin and prolactin. J. Clin. Endocrinol. Metab., 67, 460-464.
43. Poretsky, L. (1991) On the paradox of insulin-induced hyperandrogenism in insulin resistant states. Endocr. Rev., 12, 3-13.
44. Prelevic, G.M., Wurzburger, M.I., Balint-Peric, L. et al. (1990a) Inhibitory effect of sandostatin on secretion of luteinising hormone and ovarian steroids in polycystic ovary syndrome. Lancet, 336, 900-903.
45. Prelevic, G.M., Wurzburger, M.I. and Balint-Peric, L. (1990b) LH pulsatility and response to a single s.c. injection of buserelin in polycystic ovary syndrome. Gynecol. Endocrinol., 4, 1-3.
46. Shoupe, D., Kumar, D.D. and Lobo, R.A. (1983) Insulin resistance in polycystic ovary syndrome. Am. J. Obstet. Gynecol., 147, 588-592.
47. Toeller, M. (1991) Modulation of intestinal glucose absorption: postponement of glucose absorption by alpha-glucosidase inhibitors. In Mogensen, C.E. and Standl, E. (eds), Pharmacology of Diabetes. Walter de Gruyter, Berlin, New York, pp. 123-126.
48. Van der Meer, M., de Boer, J.A., Hompes, P.G. et al. (1998) Octreotide, a somatostatin analogue, alters ovarian sensitivity to gonadotrophin stimulation as measured by the follicle stimulating hormone threshold in polycystic ovary syndrome. Hum. Reprod., 13, 1465-1469.
49. Velazquez, E.M., Mendoza, S., Hamer, T. et al. (1994) Metformin therapy in polycystic ovary syndrome reduces hyperinsulinemia, insulin resistance, hyperandrogenemia, and systolic blood pressure, while facilitating normal menses and pregnancy. Metabolism, 43, 647-654.
50. White, D., Leigh, A., Wilson, C. et al. (1995) Gonadotrophin and gonadal steroid response to a single dose of a long-acting agonist of gonadotrophin-releasing hormone in ovulatory and anovulatory women with polycystic ovary syndrome. Clin. Endacrinol. (Oxf.), 42, 475-481.